JPRN-UMIN000030311已完成未知
Clinical study in new protocol of anti-VEGF agents for macular edema with retinal vein occlusion and in relation between the protocol and cytokines - Relationship between new protocol of anti-VEGF agents and cytokines for RVO
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)patients who were performed operation 2)patients with active uveitis 3)patients with rubeosis 4)patients with uncontrolled glaucoma 5)patients with severe diabetic retinopathy
研究者
相似试验
进行中（未招募）
1 期
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME) - A Study to Compare Anti-VEGF Agents in the Treatment of DME (CADME)Diabetic Macular Edema (DME)MedDRA version: 15.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2012-005486-13-GBThe National Eye Institute60
已完成
不适用
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularizatioretinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularizationJPRN-UMIN000027243School of Medicine Toho University20
招募中
1 期
Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularizatiochoroidal neovascularization diabetic retinopathy retinal vein occulusion neovascular glaucoma retinopathy of prematurity central serous chorioretinopathyJPRN-UMIN000011094Kobe University Graduate school of Medicine510
尚未招募
不适用
Evaluation of the responsiveness of anti-VEGF treatment in DMEdiabetic retinopathy (DR)NL-OMON29053GSMS70
进行中（未招募）
1 期
To Study Aqueous Humor Composition and Retinal Imaging Features in Response to Anti-VEGF in Neovascular Age-Related Macular Degeneration and Diabetic Macular EdemaTreatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME)MedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2020-003515-10-PLF. Hoffmann-La Roche Ltd200